Completed OBSERVATIONAL NCT00290849

ImproveR International (BI-001-IM)

European Registry of Consecutive Patients Undergoing PCI Evaluating the Use of the Thrombin-specific Anticoagulant Bivalirudin With Focus on Patient Selection, Convenience and Safety Aspects.

Sponsor: Nycomed

Conditions Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)

Interventions Bivalirudin

Updated 6 times since 2017 Last updated: May 4, 2012 Started: Mar 31, 2005 Primary completion: Jun 30, 2006 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00290849, this observational or N/A phase trial focuses on Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI) and remains completed. Sponsored by Nycomed, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nycomed

Data source: Nycomed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roskilde, Denmark